Connect with us

Press Release

China Medical System：First Ruxolitinib Cream’s Prescriptions for Vitiligo Issued in the Greater Bay Area

Published

2 hours ago

on

SHENZHEN, CHINA – China Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that on 18 October, the first batch of prescriptions of ruxolitinib phosphate cream (the “ruxolitinib cream” or the “Product”) for qualified vitiligo patients were issued in the Greater Bay Area, at Zhongshan Chen Xinghai Hospital of Integrated Traditional Chinese and Western Medicine, Foshan Fosun Chancheng Hospital, and Dongguan Songshan Lake Tungwah Hospital. The Product’s new drug application (NDA) was approved by the Pharmaceutical Administration Bureau (ISAF) of Macau on 11 April 2024, and subsequently the Product was approved by the Guangdong Provincial Medical Products Administration on August 19 through the “Hong Kong and Macau Medicine and Equipment Connect” policy, which officially introduced ruxolitinib cream for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age, providing a novel treatment option for patients with relevant indication into designated medical institutions in the Mainland of Greater Bay Area.

 

In addition, on 24 September, the NDA for vitiligo indication of ruxolitinib cream has been accepted by the National Medical Products Administration of China (NMPA). In accordance with the relevant regulations of the drug real-world data application pilot program in the Hainan Boao Lecheng International Medical Tourism Pilot Zone (the “Pilot Zone”), CMS has conducted a real-world study on ruxolitinib cream in China. The results have shown positive efficacy, which is consistent with the key outcomes of global pivotal clinical studies. All secondary efficacy endpoints showed a trend of benefit consistent with the primary efficacy endpoint, and the treatment effect for vitiligo continued to improve with longer treatment duration. Meanwhile, through the safety monitoring data of the Pilot Zone, no new safety events have been identified. Adverse events mostly had severity levels of grade 1 or 2. No adverse event (AE) leading to discontinuation or withdrawal, and no serious adverse event (SAE) related to the study drug occurred.

 

If the Product is successfully approved for marketing in Mainland China, it will be the first prescription drug approved by NMPA for repigmentation in vitiligo, bringing this novel treatment hopes for Chinese vitiligo patients.

 

Furthermore, on 12 August 2023, the Product was approved by Hainan Medical Products Administration for Urgent Clinical Import, and officially became available to applicable patients in the Pilot Zone on August 18, for the topical treatment of non-segmental vitiligo in adults and adolescents aged 12 and above with facial involvement. Benefiting from the Early and Pilot Implementation Policy granted by the state to Hainan Free Trade Port and the Pilot Zone, patients with vitiligo in China can apply for the Product in Boao Super Hospital first and receive treatment from the expert team. As of 30 June 2024, more than 3,200 patients have been treated with ruxolitinib cream in Boao Super Hospital.

 

CMS has always been patient-oriented and innovation-driven based on clinical needs, continuously striving to improve drug accessibility. Benefited from the “Hong Kong and Macau Medicine and Equipment Connect” policy, ruxolitinib cream was approved for use in the Greater Bay Area and completed its first batch of prescriptions, shortening the time difference for Chinese vitiligo patients to use innovative drug and benefiting more domestic patients. Looking forward to the future, the Group will continuously strive to meet the unmet needs of Chinese patients, continuously explore novel drugs with international quality, and efficiently promote products’ clinical development and commercialization, so as to bring more quality pharmaceutical products through differentiated innovation-breakthrough, to safeguard the health and life-quality of patients.

 

About ruxolitinib cream

Ruxolitinib cream (Opzelura), a novel cream formulation of Incyte’s selective JAK1/JAK2 inhibitor ruxolitinib, is approved by the U.S. Food & Drug Administration for the topical treatment of nonsegmental vitiligo in patients 12 years of age and older. As of now, it is the first and only treatment for repigmentation approved for use in the United States[1]. Ruxolitinib cream (Opzelura) is also approved in the U.S. for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable[2]. In Europe, ruxolitinib cream (Opzelura) is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age[3].

 

On 2 December 2022, the Group through a subsidiary of the Company, a dermatology medical aesthetic company (“CMS Skinhealth”) entered into a Collaboration and License Agreement (the “License Agreement”) with Incyte for topical formulations of ruxolitinib for the treatment of autoimmune and inflammatory dermatology diseases. In accordance with the License Agreement, the Group through CMS Skinhealth received an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (Indonesia, Philippines, Vietnam, Thailand, Myanmar, Malaysia, Cambodia, Laos, Singapore, Timor-Leste and Brunei Darussalam) (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The License Agreement commenced on its effective date and has a royalty term of ten years from the date of the commercial sale of the Product in the Territory (the “Royalty Term”). Upon the expiration of the Royalty Term, the License Agreement may be renewed for a period of ten years thereafter (the “Initial Extended Royalty Term”) as per certain conditions defined in the License Agreement. Upon the expiration of the Initial Extended Royalty Term, the License Agreement may be extended for a period otherwise agreed by both sides as per certain conditions defined in the License Agreement.

 

Incyte has worldwide rights for the development and commercialization of the Product, marketed in the United States and Europe as Opzelura®. Opzelura and the Opzelura logo are registered trademarks of Incyte.

 

About vitiligo

Vitiligo is a chronic autoimmune disease characterized by depigmentation of the skin, which results from the loss of pigment-producing cells known as melanocytes. It is estimated that there are approximately 14 million vitiligo patients in China[4]. Non-segmental vitiligo patients account for approximately 85% of them. Topical corticosteroids (TCS) and calcineurin inhibitors (CI) are used off-label for non-segmental vitiligo, however, these therapies have clinical deficiencies with long-term adverse reactions of long-term treatment or limited efficacy[5、6].

 

About CMS

CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.

 

CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.

 

CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries. While strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology business, CMS independently operates its dermatology and medical aesthetics business, and ophthalmology business, aiming to gain leading positions in specialty therapeutic fields, whilst enhancing the scale and efficiency. At the same time, CMS has expanded its business territory to the Southeast Asian market, striving to become a “bridgehead” for global pharmaceutical companies to enter the Southeast Asian market, further escorting the sustainable and healthy development of the Group.

 

Reference：

  1. Drug approval information can be found on the FDA official website, as follows: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-topical-t…
  2. Drug approval information can be found on the Incyte official website, as follows: https://investor.incyte.com/news-releases/news-release-details/incyte-an…
  3. Drug approval information can be found on the EMA official website, as follows: https://www.ema.europa.eu/en/medicines/human/EPAR/opzelura
  4. Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet. 2015;386(9988):74-84. doi:10.1016/S0140-6736(14)60763-7
  5. Consensus on the diagnosis and treatment of vitiligo (2021 version)
  6. Kubelis-López DE, Zapata-Salazar NA, Said-Fernández SL, Sánchez-Domínguez CN, Salinas-Santander MA, Martínez-Rodríguez HG, Vázquez-Martínez OT, Wollina U, Lotti T, Ocampo-Candiani J. Updates and new medical treatments for vitiligo (Review). Exp Ther Med. 2021 Aug;22(2):797. doi: 10.3892/etm.2021.10229. Epub 2021 May 25. PMID: 34093753; PMCID: PMC8170669.

 

CMS Disclaimer and Forward-Looking Statements

This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

 

This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

 

Media Contact

Brand: China Medical System Holdings Ltd.

Contact: CMS Investor Relations

Email: ir@cms.net.cn

Website: https://web.cms.net.cn/en/home/

Source: China Medical System Holdings Ltd.

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Related Topics:
Continue Reading

Press Release

Solar photovoltaic SPUSDT is transforming global solar energy trading market

Published

3 mins ago

on

October 18, 2024

By

The global energy market is undergoing an unprecedented transformation, with the increasing demand for clean energy driving solar photovoltaics (PV) to the forefront of this revolution. Against this backdrop, the launch of the SPUSDT platform is particularly noteworthy. By combining blockchain technology with the USDT stablecoin, SPUSDT aims to create a decentralized, transparent, and efficient platform for solar energy trading. This platform not only addresses the high costs and inefficiencies of traditional energy trading but also significantly enhances market transparency, offering solar energy producers and consumers a new and streamlined way to trade. Most importantly, by integrating USDT as a stablecoin, SPUSDT ensures price stability, reducing trading risks and increasing market liquidity and attractiveness.

According to data from the International Energy Agency (IEA), the global solar PV market has experienced explosive growth over the past decade, with an average annual growth rate of over 20% in installed capacity. In 2023, the global newly installed solar PV capacity exceeded 200 GW, setting a new record. This achievement is largely due to continuous technological advancements and a significant reduction in manufacturing costs. In recent years, the cost of solar energy generation has fallen to historic lows, with some regions now seeing solar energy priced lower than traditional energy sources. As costs continue to fall, the adoption of solar power is accelerating, especially in emerging markets where solar has become one of the most competitive power sources. By 2030, global solar PV capacity is expected to reach 3,000 GW, accounting for more than 15% of the world’s total electricity generation.

However, despite the expanding market, the solar PV industry still faces several challenges. First, the issue of transaction costs. Traditional energy trading often relies on intermediaries and complex processes, leading to high transaction costs. Second, the market lacks transparency and real-time data, with information asymmetry between participants limiting effective market operation. For small- and medium-sized energy producers and consumers, market entry barriers are high, restricting their participation. Additionally, price volatility introduces significant risks to market participants, hindering long-term investment and sustainable market development.

The SPUSDT platform was launched to address these challenges. By introducing blockchain technology, SPUSDT provides a fully decentralized trading platform where all transaction records are securely stored on the blockchain, ensuring data immutability and transparency. Blockchain’s distributed ledger technology not only reduces human intervention, ensuring fairness in transactions, but also provides real-time market data to help participants make more informed decisions. Furthermore, SPUSDT automates the trading process using smart contracts, simplifying the complexities of traditional energy trading and significantly improving transaction efficiency while reducing delays.

Additionally, by using the USDT stablecoin as the primary medium of exchange, SPUSDT effectively solves the problem of price volatility. Traditional energy markets are often influenced by changes in supply and demand, political factors, and market speculation, which lead to significant price fluctuations and increased risk for market participants. By integrating USDT into the trading process, SPUSDT eliminates the volatility associated with cryptocurrency markets, allowing both parties to complete transactions at stable prices, thus reducing uncertainty. This mechanism provides greater security for investors, encouraging more institutions and individuals to enter the solar energy market.

SPUSDT also significantly lowers the barriers to entry for the solar PV market, particularly for small producers and individual users. Traditionally, solar energy participants had to work through large power companies or intermediaries to complete transactions, and these intermediaries increased transaction costs while limiting the participation of smaller producers. Through the SPUSDT platform, individuals and small businesses can directly sell their excess solar energy to consumers without going through cumbersome intermediaries. This model not only enhances energy efficiency but also lays the foundation for the widespread adoption of distributed energy systems.

The rapid growth of the global solar PV market is not just the result of lower costs and technological advancements, but also driven by supportive policies. Many governments around the world have introduced policies that promote renewable energy, including subsidies, tax incentives, and renewable energy generation quotas, all of which have contributed to the growth of the solar energy industry. The SPUSDT platform was launched in this favorable policy environment, further driving the adoption of solar PV. By providing a transparent and fair trading platform, SPUSDT not only helps energy producers secure higher returns but also attracts more investors to participate in the development of solar energy projects, supporting the continued growth of the global clean energy industry.

Looking to the future, SPUSDT will continue to leverage its technological advantages to lead the development of the global solar energy trading market. As solar PV technology continues to advance, the cost of solar energy generation will decrease further, and SPUSDT will continue to optimize its blockchain and smart contract systems to enhance transaction security and efficiency. The platform also plans to introduce more financial tools, such as green certificates and carbon credits, to further incentivize market participants to invest in renewable energy, driving the transition and upgrading of the global energy structure.

Overall, the SPUSDT platform not only represents an innovation in solar energy trading but also provides a solid foundation for the future development of the global clean energy market. By combining blockchain technology, USDT stablecoin, and smart contracts, SPUSDT significantly enhances the efficiency, transparency, and security of energy transactions, offering an innovative solution for the sustainable development of the global energy market. In the future, SPUSDT is expected to occupy a prominent position in the global energy market, promoting the widespread adoption of clean energy, supporting the fight against climate change, and enabling the green transformation of the energy industry.

Contact name: Saif

Company name: HRG

Website https: https://hrginvestment.com/

Country: UAE

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Campus Eye Center: Comprehensive Eye Care Services Focused on Vision Health and Patient Satisfaction

Published

48 mins ago

on

October 18, 2024

By

Campus Eye Center, a leading provider of comprehensive eye care services in Lancaster, PA, is committed to delivering personalized and advanced care for all patients. Specializing in a broad spectrum of eye conditions and treatments, the clinic is dedicated to improving the community’s vision health while focusing on patient satisfaction and the latest advancements in ophthalmology. 

With a team of experienced ophthalmologists and optometrists, Campus Eye Center offers a wide range of eye care services, from routine eye exams to more complex treatments like cataract surgery and glaucoma management. Serving the Lancaster community and surrounding areas, the clinic continues to build on its reputation for excellence by providing tailored solutions that meet each patient’s individual needs. 

Advanced Eye Care Services 

A robust portfolio of eye care services is at the heart of Campus Eye Center’s offerings. The clinic provides care for common and complex eye conditions, focusing on delivering the highest quality of service with cutting-edge technology and innovative treatment options. Some of the core services include: 

Comprehensive Eye Exams 

Regular eye exams are essential to maintaining good vision health, and Campus Eye Center offers thorough, personalized eye exams for patients of all ages. During these exams, the clinic’s specialists assess overall eye health, check for refractive errors, and identify early signs of eye diseases such as glaucoma, macular degeneration, and cataracts. These comprehensive evaluations guide patients through every step of maintaining optimal vision health. 

Cataract Surgery and Treatment 

Cataracts, a common cause of vision impairment among older adults, can significantly affect a person’s quality of life. Campus Eye Center specializes in diagnosing and treating cataracts, with options ranging from non-surgical treatments to advanced cataract surgery. Using the latest techniques in cataract surgery, including laser-assisted surgery, the clinic’s ophthalmologists ensure patients experience a smoother recovery and better long-term vision outcomes. 

Glaucoma Diagnosis and Management 

Glaucoma is a serious eye condition that can lead to vision loss if not diagnosed and treated early. Campus Eye Center provides expert glaucoma care, offering early detection and advanced treatment options to prevent the progression of this condition. The clinic’s experienced specialists work closely with patients to develop individualized treatment plans, including medications, laser treatments, or surgery, to effectively manage and control intraocular pressure. 

Dry Eye Management 

Dry eye syndrome is a common but often overlooked condition that can cause significant discomfort and affect daily life. Campus Eye Center provides specialized care for individuals suffering from dry eye, offering treatments ranging from over-the-counter eye drops to advanced therapeutic options. By addressing the root causes of dry eye, the clinic helps patients achieve lasting relief from symptoms such as redness, irritation, and blurred vision. 

Pediatric Eye Care 

Recognizing the importance of early eye care for children, Campus Eye Center offers pediatric eye care services designed to detect and treat vision problems in young patients. The clinic’s pediatric eye exams identify refractive errors, amblyopia (lazy eye), and other common childhood eye conditions. Early detection and treatment of these issues ensure that children enjoy healthy vision as they grow and develop. 

Diabetic Eye Care 

Patients with diabetes are at increased risk of developing serious eye conditions, including diabetic retinopathy. Campus Eye Center provides specialized care for diabetic patients, offering regular screenings and advanced treatment options to prevent and manage diabetes-related eye complications. The clinic’s comprehensive approach helps protect and preserve the vision of diabetic patients through early intervention and ongoing management. 

Cutting-Edge Technology and Patient-Centered Care 

Campus Eye Center stands out for its commitment to utilizing the latest technology in eye care. Whether through advanced diagnostic equipment or minimally invasive surgical techniques, the clinic ensures that patients benefit from the most effective and up-to-date treatments available. This dedication to innovation is complemented by a strong emphasis on patient-centered care, with every member of the team focused on delivering personalized attention to meet the specific needs of each individual. 

The clinic’s state-of-the-art facility in Lancaster is designed to provide a comfortable and welcoming environment for patients. From the moment a patient walks in, they are greeted by a team that is attentive, compassionate, and dedicated to making their visit as seamless and stress-free as possible. 

Community Involvement and Education 

Campus Eye Center also believes in giving back to the community and actively participates in educational programs to raise awareness about the importance of eye health. By organizing vision screenings and providing educational resources, the clinic helps community members understand how to protect their eyesight and prevent vision loss. 

About Campus Eye Center 

Located in Lancaster, PA, Campus Eye Center is a full-service ophthalmology practice dedicated to providing exceptional eye care services to patients of all ages. With a team of experienced professionals and a wide range of advanced treatment options, Campus Eye Center is the go-to destination for anyone seeking top-quality eye care in the region. The clinic’s comprehensive services cover everything from routine eye exams to specialized care for complex eye conditions. 

Contact Information

  • Campus Eye Center 
  • 217 Harrisburg Ave, Suite 103 
  • Lancaster, PA 17603 
  • Phone: (717)974-9661 
  • Website: www.campuseyectr.com

Media Contact

Organization: Campus Eye Center

Contact Person: Brenda Barnhart

Website: http://campuseyectr.com/

Email: Send Email

Contact Number: +17179749661

Address: 2108 Harrisburg Pike, Suite 100, Lancaster PA 17601

Country: United States

Release Id: 18102418613

The post Campus Eye Center: Comprehensive Eye Care Services Focused on Vision Health and Patient Satisfaction appeared on King Newswire. It is provided by a third-party content provider. King Newswire makes no warranties or representations in connection with it.

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Meet the Top Landscaping Lawn Care and Tree Service Company in Clarksville TN

Published

48 mins ago

on

October 18, 2024

By

Discover why Bourne Brothers Landscaping is the leading landscaping, lawn care, and tree removal service in Clarksville, TN.

Clarksville, TN – Bourne Brothers Landscaping is proud to announce its rise as the leading provider of top-quality landscaping, lawn care, and tree services in Clarksville, TN. With a reputation built on trust, professionalism, and attention to detail, the company has quickly become the go-to choice for both residential and commercial clients seeking superior outdoor maintenance and beautification services.

Founded by experts with a passion for transforming outdoor spaces, Bourne Brothers Landscaping offers a comprehensive range of services, from landscape design and lawn care to tree trimming and removal. Whether you’re looking to enhance curb appeal, maintain a lush green lawn, or ensure the health of your trees, Bourne Brothers is equipped to meet your needs.

“At Bourne Brothers Landscaping, we are committed to delivering top-notch results that exceed expectations,” said Zebuli Bourne, owner of the company. “We understand that each property is unique, and we take pride in providing personalized solutions that not only improve aesthetics but also add long-term value to our clients’ homes and businesses.”

With the team’s extensive experience and dedication to quality craftmanship and techniques, Bourne Brothers Landscaping has earned rave reviews and repeat business from satisfied clients throughout Clarksville. Their commitment to eco-friendly practices and exceptional customer service sets them apart from the competition.

Services Offered Include:

For property owners seeking reliable, efficient, and affordable landscaping solutions, Bourne Brothers Landscaping is the trusted partner they can count on.

To learn more about Bourne Brothers Landscaping or to schedule a free consultation, visit https://www.bournebrotherslandscaping.com/ or call 931-494-0087.

About Bourne Brothers Landscaping: Bourne Brothers Landscaping is a premier landscaping company serving Clarksville, TN, specializing in lawn care, tree services, and landscape design. With a commitment to quality and customer satisfaction, they offer tailored solutions for properties of all sizes.

Media Contact

Organization: Bourne Brothers Landscaping

Contact Person: Zebuli Bourne

Website: https://www.bournebrotherslandscaping.com/

Email: Send Email

Contact Number: +19314940087

Address: 1820 Northwind Dr, Clarksville, TN 37042, United States

City: Clarksville

State: Tennessee

Country: United States

Release Id: 18102418605

The post Meet the Top Landscaping Lawn Care and Tree Service Company in Clarksville TN appeared on King Newswire. It is provided by a third-party content provider. King Newswire makes no warranties or representations in connection with it.

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST

Like Us
Follow Us
Subscribe Us
Follow Us